Merck and Moderna announced positive Phase 3 trial results for their individualized neoantigen therapy (INT) in combination with Keytruda for advanced melanoma, showing statistically significant improvements in recurrence-free and distant metastasis-free survival. This landmark success marks the first positive Phase 3 result for an mRNA-based cancer treatment and significantly boosts both companies' stock prices.
Merck and Moderna have reported groundbreaking Phase 3 trial results for their personalized cancer therapy, intismeran autogene, combined with Keytruda, for advanced melanoma. This is a significant milestone as it's the first positive Phase 3 outcome for an individualized neoantigen therapy and an mRNA-based cancer treatment, demonstrating superior efficacy over Keytruda alone. This success validates the potential of mRNA technology beyond infectious diseases and opens new avenues for cancer treatment, positively impacting both companies' long-term growth prospects and stock valuations. Traders should note the immediate surge in stock prices, reflecting strong market confidence in this innovative therapeutic approach, with potential for continued upside as the broader clinical program advances.